For the subtype of HER2-positive breast cancers, a variety of anti-HER2 antibody-based therapies and novel tyrosine kinase inhibitors have been developed and have achieved significant anti-tumor effects (44). The gene discussed is ERBB2; the disease is breast carcinoma.